Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Invested capital

Discontinued — last reported Q1 '26

Invested capital at other companies

Travel + Leisure logo
Travel + LeisureTNL
18.8%+0.1pp
Belden logo
BeldenBDC
12.2%+0.5pp
Cabot Corporation logo
Cabot CorporationCBT
14.7%-6.0pp
Unifirst logo
UnifirstUNF
6.2%-0.9pp
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
3.4%+1.8pp
Liberty Broadband Corporation logo
Liberty Broadband CorporationLBRDK
-0.3%-0.1pp

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

$81.1Mtotal debt+$278.9Mtotal stockholders equity−$40.6Mcash and equivalents=$319.33M

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's invested capital?
Allogene Therapeutics (ALLO) reported invested capital of $319.33M in Q1 2026.
How has Allogene Therapeutics's invested capital changed year-over-year?
Allogene Therapeutics's invested capital decreased by 24.3% year-over-year, from $421.57M to $319.33M.
What is the long-term trend for Allogene Therapeutics's invested capital?
Over 5 years (2020 to 2025), Allogene Therapeutics's invested capital has grown at a -18.5% compound annual growth rate (CAGR), from $874.44M to $313.82M.
What does invested capital mean?
Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).